Leadership / All Change at the Top: 2023's 13 New Pharma CEOs
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
Address: 345 Park Avenue
New York, New York
10154
Tel: 800-332-2056
Web: http://www.bms.com/pages/default.aspx
Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Bristol-Myers Squibb produces medicines against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
At Bristol-Myers Squibb, its BioPharma strategy combines a major pharma company with a successful biotech company which helps to focus on the customers’ needs giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this…
Francesco Lanucara of PharmaLex, writing in the November 2023 edition of the DIA’s Global Forum magazine takes a look at how new guidance from the US FDA aims to tackle…
Dr Vivienne Marshall, senior director of the Center for Advanced Therapies at the South Texas Blood & Tissue Center, part of BioBridge Global, outlines some of the major barriers to…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the…
The US Inflation Reduction Act (IRA) passed last year by the Biden administration and hotly contested by the innovative pharma industry, has started to look more like a reality since…
After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the…
The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a…
Having become one of the 20 youngest US billionaires as founder and CEO of disruptive biotech firm Roivant Sciences, Vivek Ramaswamy has now set his sights on becoming his country’s…
Illumina’s newly appointed CEO, Jacob Thaysen, will take the reins of the gene sequencing giant at the end of September. Falling heir to the difficulties that have plagued the company…
Biotech and life sciences companies have a habit of clustering together, creating shared ecosystems to drive innovation. For going on 12 years Johnson & Johnson Innovation (JLABS), has been supporting…
See our Cookie Privacy Policy Here